Magdalena biosciences initiates preclinical study to evaluate plant extracts to treat depression, anxiety, adhd and other mental health indications

Magdalena biosciences, a joint venture recently formed by jaguar health and filament health corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications magdalena launches corporate website san francisco, ca / accesswire / october 23, 2023 / jaguar health, inc. (nasdaq:jagx) today announced that magdalena biosciences, inc., the joint venture recently formed by jaguar and filament health corp. (otcqb:flhlf) (neo:fh) (fse:7qs) to develop novel, natural prescription medicines derived from plants for mental health indications, has initiated a preclinical study in brazil to evaluate two plant extracts for their potential to treat depression, anxiety, attention-deficit/hyperactivity disorder (adhd) and other possible neuropsychiatric conditions initially in adults. "this preclinical study will consist of evaluating both extracts in mice, using fluorodeoxyglucose positron emission tomography (fdg pet) scans to look for differential neuronal activity," said dr. karen brunke, jaguar's evp of corporate and business development and acting ceo of magdalena biosciences.
JAGX Ratings Summary
Quant
JAGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score